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Lack of targeting and improper biodistribution are major flaws in current drug-based 
therapies that prevent reaching high local concentration of the therapeutic agent. Such 
weaknesses impose the administration of high drug doses, resulting in undesired side 
effects, limited efficacy and enhanced production costs. Currently missing nanosized 
containers, functionalized for specific cell targeting will be then highly convenient for 
the controlled delivery of both conventional and innovative drugs. In an attempt to fill 
this gap, health-focused nanotechnologies put under screening a growing spectrum of 
materials as potential components of nanocages, whose properties can be tuned 
during fabrication. However, most of these materials pose severe biocompatibility 
concerns. We will revise here how proteins, the most versatile functional 
macromolecules, can be conveniently exploited and adapted by conventional genetic 
engineering as efficient building blocks of fully compatible nanoparticles for drug 
delivery, and how selected biological activities can be recruited to mimic viral behavior 
during infection. Although engineering of protein self-assembling is still excluded from 
fully rational approaches, the exploitation of protein nano-assemblies occurring in 
nature and the direct manipulation of protein-protein contacts in bioinspired constructs 
open intriguing possibilities for further development. These methodologies empower 
the construction of new and potent vehicles that offer promise as true artificial viruses 




Nanomedical approaches to drug delivery are aimed to the development of smart 
nanosized cages with high stability, appropriate pharmacokinetics and efficient cell 
penetrability. Ideally, any drug delivery system should perform a set of biological 
activities enabling them to reach an appropriate biodistribution and to deliver the cargo 
molecules to the appropriate compartment of a target cell type. Success in these 
activities would be only reached by vehicles overcoming several consecutive biological 
barriers, at both cellular and organic levels, in the absence of undesired side effects. In 
this regard, progresses in the design and fabrication of nanocontainers are in part 
restricted by the severe toxicity exhibited by some of the materials so far explored for 
nanofabrication and by the limited success in the targeting and delivery events. 
Different synthetic delivery carriers including cationic liposomes and micelles, 
polymeric nano-micro-particles, block copolymers, carbon nanotubes, dendrimers and 
inorganic nanoparticles have been actively developed and studied not only for 
facilitating targeted drug delivery but also for maximizing therapeutic efficacy (Kang et 
al., 2012). Being in general biologically inert, these materials, once nanostructured, 
must be functionalized to gain targeting abilities and other properties necessary for a 
proper biodistribution such as cell surface receptor binding, membrane crossing and 
nuclear penetration.  
 
In contrast to engineering approaches involving synthetic materials, natural or modified 
gene delivery carriers are also offering potential promises and alternatives over 
synthetic vehicles because they could accomplish most of the main requirements 
needed for an ideal delivery including biocompatibility, solubility in water and high 
uptake efficiency (Ma, Nolte, & Cornelissen, 2012). These bioengineered biological 
entities can be living or non-living bacteria, viral gene vectors, virus-like-particles, 
virosomes, cell organelles, red blood cells, immune cells and stem cells, among others 
(Yoo, Irvine, Discher, & Mitragotri, 2011). Among all these vehicles, the majority of 
clinical trials for gene therapy still use virus-based nanocarriers (Giacca & Zacchigna, 
2012). In fact, viruses, as pathogenic nanosized entities, have developed mechanisms 
and strategies successful in protecting their genomes and associated proteins and 
transport them through the extracellular environment, evading the host immune 
system, interacting with specific receptors of target cells and driving nucleic acids to the 
right cell compartment. These activities are based on the functional domains of viral 
proteins that have been continuously submitted to selective pressures during 
interaction with hosts. Therefore, as functional vehicles for targeted delivery, viruses 
offer superior advantages compared to synthetic constructs. Obviously, residual viral 
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pathogenic potential, even upon genetic inactivation, is a major concern when 




Far from such biosafety concerns, proteins themselves fulfill the requirement of 
biocompatibility as they are main structural and functional components of living beings. 
In addition, proteins, protein domains or shorter polypeptide stretchespeptides are 
responsible for most of the cross-molecular interactions, biochemical reactions, 
transformations and regulation events supporting life. Therefore, the ability of proteins 
to form supramolecular complexes but also to carry out functions relevant to targeted 
delivery make them appealing building blocks of nanocages for therapeutic purposes. 
In addition, they can be produced at industrial scale by recombinant DNA technologies 
(Ferrer-Miralles, Domingo-Espin, Corchero, Vazquez, & Villaverde, 2009). Many of 
these functions, especially those responsible for specific intermolecular contacts, have 
been mapped in surface-exposed regions of polypeptides proteins and they can be 
performed by linear peptides. Unlike complex biological protein production, the 
straightforward chemical synthesis of peptides benefits from the potential to incorporate 
unnatural amino acids and to introduce chemical modifications. Also, inter-batch 
variability is minimized and the quality concerns associated to recombinant protein 
production, such as conformational stress and midstream and downstream aggregation 
(Vazquez, Corchero, & Villaverde, 2011), are avoided. The lower functional plasticity, 
when compared to full-length natural or engineered proteins,proteins might be 
balanced by the high control of the amino acid sequence and physicochemical 
properties of the products. 
 
However, protein functions can be also adjusted tailored in natural polypeptides or in 
fully de novo designed proteins through conventional genetic engineering. Since late 
70’s, the progressive development of cell factories and genetic tools for protein 
modification and production allowed the small and large scale fabrication of modified 
proteins as drugs, what has expanded the bio-pharma industries, with almost 200 
protein drugs currently in use for human therapies. The enormous functional diversity 
of proteins in nature includes activities that would be highly convenient in targeted drug 
delivery, such as binding and condensation of nucleic acids, specific interactions with 
cell surface receptors, receptor-mediated endocytosis, endosomal escape, cytosolic 
trafficking and nuclear transport (Vazquez, Ferrer-Miralles, & Villaverde, 2008; Aris & 
Villaverde, 2004; Ferrer-Miralles, Vazquez, & Villaverde, 2008). In fact, the combination 
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of such abilities in viral capsids characterizes the virus life cycle and permits the 
horizontal transmission of both proteins and nucleic acids during infection. Being 
viruses the main referent in the design of functional protein-based nanoparticles for 
gene transfer, the artificial virus concept (Douglas, 2008; Mastrobattista, van der Aa, 
Hennink, & Crommelin, 2006; Wagner, 2004) orbits around the possibility to mimic 
these abilities in manufactured or recombinant constructs of viral size, devoid of any 
infectious material and being then chemically and biologically safe. While rRecruiting 
desired functions by the combination of active peptides, protein domains or modular full 
proteins (for instance, as multifunctional proteins) seems to be an affordable task. 
However engineering self-assembling of the forming building blocks is still excluded 
from a rational approach (Vazquez & Villaverde, 2010). Indeed, lack of controlled self-
assembling as nanoparticles of pre-defined properties is probably the main obstacle to 
the construction of highly desired protein-only nanoscale shells as biomimetic of natural 
viruses. The potential therapeutic value that protein-coding nucleic acids as well as 
non-coding nucleic acids (such as small regulatory RNAs, DNA oligonucleotides, small 
catalytic RNAs and DNAs, long antisense RNAs, decoy RNAs and aptamers) is 
gaining, points out nucleic acids as main therapeutic drugs in a next future for a wide 
spectrum of potential applications (Giacca & Zacchigna, 2012). This fact makes the 
artificial virus concept (namely, the full adaptation of nanocages to the particular 
delivery of nucleic acids) highly promising in nanomedicine. Protein self-assembling 
into nucleic acid-embracing shells is here mandatory, as nucleic acids are highly labile 
molecules. 
  
Naturally occurring, self-assembling protein nanoparticles 
Viruses 
Viral life cycle is supported by self-assembling protein nanoparticles that efficiently 
interact with host cells and deliver their cargo genome to the correct cell compartment. 
In the gene therapy arena, viruses have been exploited as nucleic acid-containing 
delivery agents, due to its specificity in cell-surface receptor binding, cell penetrability 
and efficient nucleic acid delivery (Limberis, 2012; Giacca & Zacchigna, 2012). More 
than 1800 ongoing or completed gene therapy clinical trials have been recorded, most 
of them using species from the families Adenoviridae, Parvoviridae, and Retroviridae 
(Table 1), upon engineering to include the desired transgene and to eliminate their 
replicative potential (http://www.wiley.com/legacy/wileychi/genmed/clinical/). 
Adenovirus are linear dsDNA icosahedral non-enveloped virus with a capsid composed 
by three major capsid proteins and four minor capsid proteins forming viral particles of 
approximately 90 nm (Martin, 2012; Vellinga, Van der Heijdt, & Hoeben, 2005). 
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Adenovirus-based vectors have a large packaging capacity and can transduce several 
cell cultures and tissues in vivo. However, transient transgene expression level 
depends on the immune response of the host that might be highly activated. Actually, a 
fatal systemic inflammatory response syndrome was reported in a patient enrolled in a 
safety gene therapy trial of second generation adenovirus vector, highlighting the 
limitation of the animal models used in preclinical trials and the need of determining the 
patient-to-patient immunogenic variability (Raper et al., 2003; Smaglik, 1999). On the 
other hand, adeno-associated vectors (Parvoviridae) have reduced packaging capacity 
but can transduce dividing and non-dividing cells, which is quite convenient when 
treating diseases affecting non-growing tissues. It has been demonstrated that the 
double strand DNA of adeno-associated vectors can integrate randomly in the genome 
of the transduced cell (Giacca & Zacchigna, 2012). However, in preclinical and clinical 
trials performed so far, no integration events have been documented. Finally, 
Gammaretrovirus and Lentivirus, both genus of the Retroviridae family, are also under 
exploration for gene therapy purposes. Gammaretrovirus have a large packaging 
capacity and a high level of stable transgene expression. Lentiviruses show the same 
properties than their Gammaretrovirus counterparts but can also transduce non-
dividing cells. Nevertheless, in both cases, the encapsulated RNA, once reverse 
transcribed, is integrated in the host genome, which can result in undesired insertional 
mutagenesis. This has been already disclosed in clinical trials for patients suffering 
from X-linked severe combined immunodeficiency (SCID-X1). These patients were 
reinfused with CD34+ cells treated ex vivo with retroviruses containing the cytokine 
receptor gamma gene. Some of the patients developed leukemia linked to the random 
insertion of the retroviral DNA (Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et 
al., 2003b; Howe et al., 2008).  
 
In China, the State Food and Drug administration (SFDA) approved, a few years ago, 
two viral gene therapy drugs, namely Gendicine (Gao, 2011) and Oncorine (Liang, 
2012). Gendicine is an adenovirus vector containing p53 gene that has been already 
tested in more than 50 types of solid tumours. Oncorine is a conditional replicative 
oncolytic adenovirus–based vector that only replicates in cancer target cells that result 
are then lysed. Although the results obtained by Chinese gene therapy products based 
on viral vectors have been met with skepticism by the scientific community (Guo & Xin, 
2006), the high number of ongoing clinical trials in this field advancing towards 
improved methodologies to overcome secondary effects might initiate a new era in the 
treatment of genetic diseases. The reluctance of USA and European regulatory 
agencies (FDA and EMA) to approve viral-based drugs for gene therapy (linked to the 
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adverse effects and to the requirement to demonstrate a significant increase in overall 
survival rate) was finally broken by the very recent (November, 2012) approval of 
Glybera (alipogene tiparvovec), that is based on a modified adeno-associated virus 
(AAV) of serotype 1. This approval derives from a tortuous administrative process 
involving four revisions by the EMA and by the Committee on Human Medicinal 
Products (CHMP). Such bottlenecks resulted, which led  in the withdrawal of the 
company that initially presented the product (Amsterdam Molecular Therapeutics), 
which was. This company was finally replaced by UniQure in achieving the approval 
(Yla-Herttuala, 2012). Glybera is intended to treat a rare disease called lipoprotein 
lipase deficiency (LPLD), also known as familial hyperchylomicronemia, whose patients 
suffer recurring acute pancreatitis (http://www.uniqure.com/products/glybera/). Glybera 
delivers a normal, healthy LPL gene packaged in the AAV-based vector with tropism by 
to muscle cells, the natural LPL producers, and it was tested in three clinical 
interventional studies conducted in the Netherlands and in Canada, in only 27 LPLD 
patients. The drug is administered via a one-time series of small intramuscular 
injections in the legs, and the approval for this prescription is under exceptional 
circumstances, and only allowed in selected centers of excellence with expertise in 
treating LPLD. Furthermore, Advexin, an adenovirus-based vector for p53 tumour 
suppressor therapy, is expected to be approved by the FDA after successfully ended 
phase III clinical trials.  
 
In the line of safest approaches, bacteriophages have been extensively explored as 
vehicles as they can display foreign peptides or proteins to target specific cell types 
(Clark & March, 2006). In fact, phage display technology allows the identification of 
tissue-homing peptides to target tumors in potentially personalized treatments (Krag et 
al., 2006), that can be then used to functionalize nanovehicles of different chemical 
nature or just exposed to phages’ surface itself (Khalaj-Kondori, Sadeghizadeh, 
Behmanesh, Saggio, & Monaci, 2011; Pan et al., 2012b). In fact, conventional genetic 
engineering can be used to modify the tropism of not only bacteriophages but also 
animal viruses, opening a door for flexibility and potential design of targets. This should 
enable the interaction with receptors overexpressed in target tissues that might 




Virus-like-particles (VLPs) are tuneable nanometric virus coat-protein cages produced 
in recombinant cells (usually insect cell lines but also microorganisms) through the 
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controlled expression of one or more cloned structural genes from a given viral species 
(Palomares, Mena, & Ramirez, 2012). VLPs mimic supramolecular (hierarchical) self-
assembly behavior of viruses and are non-infectious, non-replicative and then safer 
than viral vectors. One or few major viral structural capsid proteins (not necessarily all 
those forming natural capsids) can spontaneously self-assemble into highly organized, 
homogeneous and morphological defined nanoparticles with uniform size (ranging from 
10 to 1000 nm) and shape distributions (icosahedraons, spheres or tubes) with high 
stability (Ma, Nolte, & Cornelissen, 2012; Lee, Nguyen, & Wang, 2011). VLPs of 
diverse viruses such as papillomaviruses, hepatitis B, C and E viruses, polyoma 
viruses, lentiviruses, rotaviruses, parvoviruses, noroviruses, and the particular species 
CCMV, CPMV, MS2, M13, or Qβ have been so far generated (Lee & Wang, 2006; Ma, 
Nolte, & Cornelissen, 2012). 
 
Moreover, disassembly and reassembly of VLPs can be controlled in vitro (Mellado et 
al., 2009) resulting into natural empty “shells”, “hollow scaffolds” or “nano-containers” 
that are also suitable for ex vivo packaging and loading of therapeutic cargo molecules 
such as dyes, quantum dots, magnetic nanoparticles, chemicals, foreign proteins and 
exogenous nucleic acids. In addition, VLPs conserve some unique properties of the 
natural infective particles such as natural tropism, cellular uptake and intracellular 
trafficking. A broad range of organs can be targeted with different VLPs, including liver 
(hepatitis B VLPs), spleen (some papilloma and polyoma VLPs), antigen presenting 
cells (certain papilloma VLPs), and glial cells (JC virus VLPs), among others (Seow & 
Wood, 2009).  
 
While VLPs were initially developed for vaccination purposes, they have recently 
emerged as biocompatible self-assembling nanomaterials in form of bioimaging 
scaffolds, nanowires and nanocomposites (Manchester & Singh, 2006). As nanocages, 
VLPs are superior to conventional viral vectors as their production is fully scalable and 
result in large yields from cost-effective production processes (Pattenden, Middelberg, 
Niebert, & Lipin, 2005), even in microbial cells (Lunsdorf, Gurramkonda, Adnan, 
Khanna, & Rinas, 2011; Rodriguez-Limas, Tyo, Nielsen, Ramirez, & Palomares, 2011). 
Moreover, VLPs resist purification processes better than viral counterparts, making 
easier the further functionalization and modification of their surfaces. In this context, 
VLPs exhibit a tunable architecture that enables their loading with diverse cargoes and 
the improvement of cell-specific targeting.  
 
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
9 
 
VLPs of different viruses including cowpea chlorotic mottle virus (CCMV), the brome 
mosaic virus (BMV), polyomavirus (such as the Simian virus (SV40) and the human 
polyoma JC virus) and papillomavirus (Lee & Wang, 2006; Ma, Nolte, & Cornelissen, 
2012) have been used, through in vitro assembly and disassembly hierarchical 
processes as well as through osmotic shock, to package and eventually deliver 
exogenous DNAs (Fang et al., 2012), oligonucleotides (Mateu, 2011), peptides and 
proteins (Henke, Rohmann, Bertling, Dingermann, & Zimmer, 2000; Kaczmarczyk, 
Sitaraman, Young, Hughes, & Chatterjee, 2011), small interfering RNAs and plasmids 
expressing short hairpin RNAs (Chou et al., 2010), small chemicals (Zhao et al., 2011), 
quantum dots (Li et al., 2009) and magnetic nanoparticles (Goicochea, De, Rotello, 
Mukhopadhyay, & Dragnea, 2007).  
 
Further, VLP inner surfaces can be genetically engineered and/or chemically modified 
to incorporate directed functionalities allowing the attachment of different small 
molecules, smaller nanoparticles, drugs or genes. The most common approach of 
chemical bioconjugation is based on the identification of endogenously exposed amino 
acid residues (such as lysines, cysteines, tyrosines, aspartic acid or glutamic acid) with 
highly reactive sites (amino, carboxylic acid, thiol and phenol groups) that permit 
targeted molecular anchoring (Qu et al., 2004) without compromising the structure and 
functionality of VLPs (Ma, Nolte, & Cornelissen, 2012; Patel & Swartz, 2011; Lee, 
Nguyen, & Wang, 2011). For example, Pan and coauthors loaded human pre-miR146a 
RNA into bacteriophage MS2 VLPs by chemical conjugation with the trans-activator of 
transcription (Tat) 47–57 peptide. This strategy offers a novel miRNA delivery system 
to promote delivery and subcellular localization of miR-146a with the effective 
suppression of the targeting gene (Pan et al., 2012a). Recently, it has been described 
an efficient, easy and convenient production of multifunctional VLPs composed by the 
major structural protein VP6 of RVrotavirus (RV). VP6, refolded from Inclusion Bodies 
(IBs) was covalently loaded with the anticancer drug DOX and subsequent self-
assembled into VLPs (Zhao et al., 2011). Similarly, it has been reported the delivery of 
active Gag-Cre recombinase, Gag-Fcy::Fur, and Gag-human caspase-8 proteins using 
avian retrovirus VLPs (Kaczmarczyk, Sitaraman, Young, Hughes, & Chatterjee, 2011). 
 
On the one hand, outer-surfaces confer the natural tropism of the virus for the cell 
targeting of VLPs and their cargoes. Also, outer VLPs surfaces can be chemically 
modified via bioconjugation through the attachment of appropriate cell-surface receptor 
ligands (such as folic acid or lactobionic acid), or alternatively, genetically engineered 
through the insertion into solvent-exposed loops of specific binding domains 
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(Stubenrauch, Gleiter, Brinkmann, Rudolph, & Lilie, 2001; Gleiter & Lilie, 2001) such as 
short peptides, antibodies, transferrin or cell penetrating peptides among others. These 
strategies for tropism modification, successfully applied in CPMV, CCMV, TMV and the 
bacteriophages Qβ, MS2, and M13 have been reviewed elsewhere (Lee & Wang, 
2006; Strable & Finn, 2009; Mateu, 2011; Ma, Nolte, & Cornelissen, 2012).  
 
In addition, it has been demonstrated (Zhao et al., 2011) that Doxorubicin-loaded VLPs 
decorated with lactobionic acid (LA chemically bound to the reactive amino groups of 
the VP6 capsid proteins) gained specific targeting to the hepatoma cell line HepG2. 
More recently, it has been developed a novel microRNA delivery system based on 
bacteriophage MS2 virus-like particles, chemically conjugated with the HIV-1 Tat47–57 
peptide (Pan et al., 2012a). Moreover, VLPs chimeras have been generated by 
conventional genetic engineering resulting in the incorporation of cell-specific short 
peptides to phage M13 for tumor targeting (Chen et al., 2004), and of a liver cell–
binding ligand (preS1) to hepatitis B core antigen (HBcAg) VLPs (Lee, Tey, Ho, & Tan, 
2012). In addition, VLPs can be modified with polymers in order to improve their half-
life, reduce immunogenicity and to stabilize cargo nucleic acids (Ma, Nolte, & 
Cornelissen, 2012). In this context, a novel polyethyleneimine-coated adeno-
associated VLP formulation (PEI-AAV2-VLP) has been generated that show high 




Bacteria are microorganisms with a complex subcellular architecture (Bobik, 2006; 
Cheng, Liu, Crowley, Yeates, & Bobik, 2008; Gitai, 2005; Rudner & Losick, 2010). 
Many bacterial species contain self-organizing nano- and micro-compartments 
(bacterial microcompartments, or BMCs) consisting of virus-like protein-only shells with 
60 to 10,000–20,000 self-assembled copies of one or a few protein species. These 
organelles package enzymes involved in specific metabolic pathways, confining such 
reactions and their putative unstable or toxic intermediate metabolites. Carboxysomes, 
the firstly identified bacterial organelles, were described in 1973 (Shively, Decker, & 
Greenawalt, 1970; Shively, Ball, Brown, & Saunders, 1973) as polyhedral inclusions of 
100–150 nm in cross section, with a 3-4 nm protein shell composed of six to ten 
different proteins. Carboxysomes contains the RuBisCO enzyme (Shively, Ball, Brown, 
& Saunders, 1973) and the carbonic anhydrase enzyme, responsible of the conversion 
of HCO-3 to CO2, the substrate for RuBisCO (Price, Coleman, & Badger, 1992; So et 
al., 2004; Yu, Price, Song, & Badger, 1992). The function of carboxysomes is to 
enhance autotrophic CO2 fixation at low CO2 levels. This role is supported by the 
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findings that carboxysome formation is induced by CO2 limitation (McKay, Gibbs, & 
Espie, 1993) and that mutant strains unable to properly form carboxysomes require 
high CO2 levels for autotrophic growth (English, Jin, & Shively, 1995; Price & Badger, 
1989).  
 
Other BMC proteins were later found encoded by the propanediol utilization operon 
(pdu operon) of Salmonella (Chen, Andersson, & Roth, 1994) and by an operon for 
metabolizing ethanolamine (eut operon) in enteric bacterial species, including 
Salmonella and Escherichia (Kofoid, Rappleye, Stojiljkovic, & Roth, 1999). Salmonella 
enterica forms a polyhedral organelle when growing on 1,2-propanediol (1,2-PD) as 
unique carbon and energy source (Bobik, Havemann, Busch, Williams, & Aldrich, 
1999). S. enterica forms structures similar in size and shape to carboxysomes during 
growth on 1,2-PD but not during growth on other carbon sources (Bobik, Havemann, 
Busch, Williams, & Aldrich, 1999; Havemann, Sampson, & Bobik, 2002). More recently, 
Sutter and colleagues (Sutter et al., 2008) described the smallest (20–24 nm of 
diameter) known protein-based organelle in the hyperthermophilic bacterium 
Thermotoga maritima. This protein family was initially named “linocins” (Valdes-Stauber 
& Scherer, 1994), but it was renamed by the authors as ”encapsulins”. 
 
Carboxysomes are approximately icosahedral in shape, as revealed by electron 
microscopy studies. As in isometric viral capsids, the construction of such structures 
typically requires a combination of hexameric and pentameric units. The typical BMC 
domain consists of 90 amino acids in length with an alpha/beta fold pattern (Kerfeld et 
al., 2005; Yeates, Crowley, & Tanaka, 2010). BMC proteins self-assemble to form disc-
shaped hexamers, the basic building blocks of the shell (Figure 1, green proteins). 
Such hexamers further assemble side-by-side, forming a flat molecular layer (Kerfeld et 
al., 2005; Tanaka et al., 2008; Tanaka, Sawaya, & Yeates, 2010). On the other hand, 
pentamers occupy the vertices of the icosahedral shell, generating curvature in an 
otherwise flat hexagonal sheet. Supporting this, homologous proteins CcmL and 
CsoS4A from two different types of pentamers (Figure 1, blue proteins), compatible 
with their placement at the vertices of 12 pentamer-icosahedral shells (Tanaka et al., 
2008). Other BMCs do not follow this architectonic pattern. For example, the 
homologous protein of CcmL and CsoS4 in the Eut microcompartment is EutN, whose 
oligomeric status is hexameric, what is reflected in the structural differences (more 
irregular in shape) found between Eut and carboxysome microcompartments. In 
general, Eut (and also Pdu) microcompartments do not resemble regular icosahedrons 
as closely as the carboxysome does. 
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Mechanisms directing enzyme encapsulation within protein-based bacterial organelles 
have been recently elucidated. In some cases, a stretch of a few (~15-20) amino acids 
at the N-terminus of the inner cargo protein directs and binds it to specific sites on the 
inner surface of the shell protein. Then, in β carboxysomes, the protein CcmM is used 
as a scaffold to form interactions between shell proteins and enzymes (Cot, So, & 
Espie, 2008; Long, Badger, Whitney, & Price, 2007), through a CcmM C-terminal 
region with homology to the small subunit of RuBisCO (Price, Howitt, Harrison, & 
Badger, 1993). In Pdu microcompartments, some of the cargo enzymes are also 
encapsulated by N-terminal targeting sequences (Fan et al., 2010; Parsons et al., 
2010). Interestingly, carboxysomes can self-assemble in vivo when RuBisCO has been 
deleted (Menon, Dou, Heinhorst, Shively, & Cannon, 2008), offering appealing 
opportunities to fill such nanocages with therapeutic molecules. A second example of 
this encapsulation strategy was provided by Sutter and colleagues (Sutter et al., 2008), 
regarding packaging of different proteins within encapsulins. In many bacteria, the 
encapsulin gene is being preceded, within an apparent two-gene operon, by the gene 
encoding either an iron-dependent peroxidase (DyP) or a protein closely related to the 
iron transporter ferritin (Flp). Sequence alignment of DyP and Flp genes revealed that 
only those followed by the encapsulin gene carry a C-terminal extension with a 
conserved amino acid sequence, responsible for the protein’s physical interaction with 
the encapsulin protein, through the binding to the inner shell surface (Sutter et al., 
2008). 
 
In a second route, there is not a directing peptide present in the cargo protein, but it is 
synthesized together with the shell-forming domain from one unique gene. In the 
hyperthermophilic archaeon Pyrococcus furiosus, a Flp coding sequence (without any 
targeting sequence directing its encapsulation by physical interaction with BMC 
proteins) is found fused in frame with an encapsulin gene (Sutter et al., 2008). Thus, 
both cargo and encapsulin proteins are synthesized as a fusion that further self-
assembles to form a nano-cage containing the cargo protein in its inner space. 
 
Specific targeting sequences could be of use in nanomedical applications to package 
proteins inside the stable self-assembled icosahedral shell of encapsulin. As an 
example, an icosahedral enzyme complex, lumazine synthase, was engineered to 
encapsulate target molecules by means of charge complementarity. The lumazine 
synthase from Aquifex aeolicus (AaLS) forms icosahedral capsids large enough to 
encapsulate proteins. The electrostatic charge within the capsid was modified by 
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replacing in each monomer four residues projecting into the lumen to glutamates, thus 
providing extra negative charges to the inner surface of the cage. On the other hand, 
the addition of a short stretch of positively charged amino acids to the cargo protein 
promoted its specific encapsulation by means of charge complementarity, as was 
demonstrated with a modified GFP containing ten arginine residues (Seebeck, 
Woycechowsky, Zhuang, Rabe, & Hilvert, 2006). Another packaging strategy would by 
the use of peptides naturally directing enzyme packaging into BMCs. In this regard, a 
short N-terminal sequence of propionaldehyde dehydrogenase (PduP) is required for 
its efficient packaging into the Pdu BMC. Fusion of this short (18 amino acids) N-
terminal stretch from PduP to GFP, GST, or maltose-binding (Fan et al., 2010), and to 
green fluorescent protein or glutathione S-transferase proteins (Fan & Bobik, 2011) 
resulted in their successful encapsulation within Pdu BMC. As many peptides targeting 
to the vasculature of a variety of tissues, organs, and tumors have been identified 
(Pasqualini & Ruoslahti, 1996b; Pasqualini & Ruoslahti, 1996a), they can be used to 
functionalize BMC, as demonstrated for a small Hsp cage structure modified with the 
peptide RGD-4C or conjugation with an anti-CD4 monoclonal antibody (Flenniken et 
al., 2006). Release of the cargo in target cells can be enhanced by using polyhistidine 
tags, a powerful membrane-disrupting agent (Ferrer-Miralles et al., 2011), to promote 
pH-dependent disassembly in the endosomes (Dalmau, Lim, & Wang, 2009a; Dalmau, 
Lim, & Wang, 2009b). As far as we know, no nucleic acids have been encapsulated 
into BMCs to date. 
 
Finally, flagella are also self-assembling protein-based bacterial nano-structures, 
organizing as nanotubes. Flagella are protein filaments involved in motility, up to 10-15 
µm in length with a typical diameter of 12-25 nm, that consist of a helical assembly of 
the flagellin protein, with 11 protein subunits per helix turn (Macnab, 2003; Yonekura, 
Maki-Yonekura, & Namba, 2003). Engineered flagella can function as bionanotube 
scaffolds, displaying functional groups on their surfaces. So far, several peptides and 
proteins have been successfully displayed into flagella for use as an analytical tool 
(Tripp, Lu, Bourque, Sookdeo, & McCoy, 2001; Westerlund-Wikstrom, 2000). However, 
tThe investigation exploration of flagella as potential vehicles to deliver nucleic acids or 
drugs  artificial viruses or generic delivery agents ishas been so far  still very 
limitednarrow. 
 
Artificial, self-organizing protein constructs 
Inclusion bodies 
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Bacterial IBs are self-organizing protein-based amyloid granules, ranging between ~50 
and 1000 nm, often occurring in the cytoplasm of the bacterium Escherichia coli when 
producing recombinant proteins. IBs are formed by a stereospecific protein-protein 
contacts (Speed, Wang, & King, 1996) based on cross-beta sheet interactions 
(Gonzalez-Montalban, Garcia-Fruitos, Ventura, Aris, & Villaverde, 2006), leading to a 
selective protein deposition with a high degree of purity (Morell et al., 2008). 
Interestingly, although IBs have been traditionally considered by-products of 
recombinant protein production processes, these nanoparticles show potential in 
different biomedical applications (Garcia-Fruitos et al., 2012) apart from as biocatalysts 
(Garcia-Fruitos & Villaverde, 2010) with tuneable biological activity (Garcia-Fruitos et 
al., 2007). Additionally, these protein-based nanoparticles are mechanically stable 
(García-Fruitós et al., 2009), showing regulatable size (García-Fruitós et al., 2009), 
geometry (Garcia-Fruitos, Seras-Franzoso, Vazquez, & Villaverde, 2010), density 
(Peternel, Jevsevar, Bele, Gaberc-Porekar, & Menart, 2008), Z-potential, stiffness and 
wettability (Diez-Gil et al., 2010). Importantly, it is feasible to obtain IBs formed by 
almost any protein of interest, eventually assisted by pull-down peptides that act as 
fuzzy architectonic tags (Nahalka & Nidetzky, 2007; Zhou, Xing, Wu, Zhang, & Lin, 
2012; Wu, Xing, Zhou, & Lin, 2011; Garcia-Fruitos et al., 2005). As IBs show high cell 
membrane penetrability (Figure 2) in absence of cytotoxicity and side effects at organic 
level, and the IB protein is made available to the cell upon uptake, IBs fabricated with 
therapeutic proteins act as unexpected vehicles for protein-based cell therapy 
(Villaverde et al., 2012; Vazquez et al., 2012; Liovic et al., 2012; Villaverde, 2012), in 
form of Nanopills (administered in suspension) or Bioscaffolds (used as substrates for 
mammalian cell growth) (Table 2). In both presentations, IBs act as biomimetics of 
secretory granules from the endocrine system, and like them, they can be considered 
non-toxic functional amyloids (Maji et al., 2008; Mankar, Anoop, Sen, & Maji, 2011) for 
the slow release of their forming proteins from a porous, fibrous protein scaffold (Cano-
Garrido et al., 2012). IBs, in addition, are excellent models to study in vivo amyloid 
assembling and their inhibitors (Espargaro, Villar-Pique, Sabate, & Ventura, 2012; 
Villar-Pique, Espargaro, Sabate, de Groot, & Ventura, 2012; Villar-Pique & Ventura, 




Many natural or in-silico designed peptides (amyloidgenic or amphiphilic) 
spontaneously self-assemble in higher order structures. Such self-organizing 
processes can be controlled by extrinsic parameters such as temperature, ionic 
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
Código de campo cambiado
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
Código de campo cambiado
15 
 
strength, pH, and the nature of the solvent, as well as by intrinsic physicochemical 
properties that can be adjusted by the modification of the amino acid sequence or the 
conjugated chemical groups. Self-assembling of short peptides occurs by non-covalent, 
weak cross-molecular local contacts between monomers including the formation of 
disulphide bridges and water-mediated hydrogen bonds, induction of turns, and 
hydrophobic, electrostatic, π-π staking and van der Waals interactions (Nisbet & 
Williams, 2012; Liu & Zhao, 2011). This result in the formation of a diversity of 
hierarchical 0 dimensional (0 D), 1D, 2D and 3D structures within the nanoscale 
including fibrils, tubes, spheres, ribbons, vesicles, micelles, monolayers, bilayers, 
hydrogels and tapes. Many amyloidogenic peptides render fibers that can organize as 
hydrogels and other valuable biomaterials with biomedical potential (Lakshmanan, 
Zhang, & Hauser, 2012; Sadatmousavi, Soltani, Nazarian, Jafari, & Chen, 2011; Liu & 
Zhao, 2011; Liu et al., 2011; Kyle, Aggeli, Ingham, & McPherson, 2010; Gelain, 
Unsworth, & Zhang, 2010; Yang et al., 2009). Unfortunately, no regular cages have 
been so far constructed with short self-assembling peptides. Also, when fused to large 
proteins and produced in biological systems, these tags promote the aggregation of the 
fusion protein into IBs (Wu, Xing, Zhou, & Lin, 2011), proving that they can even drive 
the formation of IBs, but these agents are not valuable as fine architectonic tags in 
larger modular protein constructs, at least under a straightforward fusion approach. 
 
However, cationic peptides combined with nucleic acids might form micro- (Plank, 
Tang, Wolfe, & Szoka, Jr., 1999) or nanosized particles (Domingo-Espin et al., 2011a) 
useful in gene therapy probably due to the condensation of plasmid DNA molecules. In 
fact, the DNA itself often stabilizes the protein incorporated into the complex through 
charge neutralization (Domingo-Espin et al., 2011a). Size and properties of these 
polyplexes are unpredictable and so far excluded from rational engineering. Despite 
this fact, bi-functional (Harbottle et al., 1998) or multifunctional (Domingo-Espin et al., 
2011a) peptides have been extensively explored as valuable nucleic acid-condensing 
and delivery agents in non-viral gene therapy (Dietrich, Durr, & Koch, 2012; Said, 




Proteins are natural building blocks of viruses and intracellular microbial organelles as 
discussed above. Genetic engineering technologies make possible the rational design 
of new polypeptides with desired structure or activities, and the screening of randomly 
generated large peptide/protein libraries for specific functions. In non-viral gene 
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therapy, multifunctional modular proteins have been constructed as a strategy to 
recruit, in a single polypeptide chain, all functions required for in vitro condensation and 
further cell-targeted delivery of nucleic acids (Aris & Villaverde, 2004; Vazquez et al., 
2009; Vazquez, Ferrer-Miralles, & Villaverde, 2008; Ferrer-Miralles, Vazquez, & 
Villaverde, 2008). This enables the biological production of such polypeptides in cell 
factories through cost-effective production and purification processes (Rodriguez-
Carmona & Villaverde, 2010; Vazquez & Villaverde, 2010). Such a versatile approach 
has resulted into the generation of diverse categories of protein/DNA complexes as 
non-viral vehicles, able to deliver therapeutic nucleic acids both in cell culture and in 
vivo. As a representative example, engineered β-galactosidases displaying functional 
peptides in several solvent-exposed loops, promote the functional recovery of brain-
damaged rats in ischemia models (Peluffo et al., 2003; Peluffo et al., 2006; Peluffo et 
al., 2011). The most common functional modules incorporated in thisese kind of 
constructs (cell receptor binding, DNA condensation, nuclear transport and endosomal 
escape) do not show any particular architectonic potential. Therefore, the size and 
geometry of the resulting polyplexes is unpredictable and it results from the tendency of 
the engineered protein to form supramolecular complexes, combined with the 
electrostatic interactions generated between protein and DNA. For instance, large 
molecular weight β-galactosidases (about 120 kDa per monomer, tetrameric in their 
original form) organize as amorphous, largely polydisperse entities (small soluble 
aggregates in the nanoscale) when empowered with cationic peptides displayed at the 
protein’s surface (Aris & Villaverde, 2000; Aris & Villaverde, 2003). The further addition 
of plasmid DNA has then a poor influence in this architecture, and the resulting 
polyplexes remain essentially unchanged. In contrast, shorter multifunctional peptides 
of about 20 kDa, based on the sequential joining of active amino acid segments, tend 
to precipitate as large size aggregates. The further addition of plasmid DNA stabilizes 
the protein building blocks, what results in the generation of polyplexes as 
monodisperse and fully soluble nanoparticles of 80 nm, extremely efficient in the 
delivery of the cargo DNA (Domingo-Espin et al., 2011b).  
 
While true architectonic tags to be incorporated as an extra module of multifunctional 
proteins remain to be identified, a recent engineering approach shows promise to 
create and pre-define the self-assembling properties of building blocks in the 
construction of artificial viruses. The combination of an amino-terminal cationic peptide 
and a carboxy-terminal polyhistidine, when flanking a core protein (can be as diverse 
as GFP or p53), promote the generation of dipolar building blocks that tend to self-
organize as rather planar nanoparticles of defined size (Unzueta et al., 2012b). Such 
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self-assembling is empowered at slightly acidic pHs, when the imidazole group of the 
histidines result protonated (Ferrer-Miralles et al., 2011). This in turn confers them 
cationic charge while it also activates the potential of this residue in acting as proton 
sponge for endosomal escape. Interestingly, the size of the resulting nanoparticles is 
directly proportional to the number of cationic residues in the amino-terminal tag 
(Unzueta et al., 2012b). Differently lengthened polyarginines as well as naturally 
occurring cationic protein segments (such as T22, R9 or A5), are valuable as 
architectonic regulators at the amino terminus (Unzueta et al., 2012b). Once formed, 
the resulting nanoparticles are highly stable at physiological pH, show a correct 
biodistribution once injected in model animals and efficiently reach the target cell 
compartment (Unzueta et al., 2012a). Loaded with DNA, R9-empowered members of 
this family of artificial viruses promote nuclear delivery of expressible DNA (Vazquez et 
al., 2010a; Vazquez et al., 2010b). Although this nanoscale architectonic principle is 
just in its infancy, it opens so far unexpected ways to engineer shape and function in 
recombinant protein-based artificial viruses by the incorporation of architectonic tags to 
building blocks. 
 
Conclusions and future prospects  
Different categories of self-assembling protein-based building blocks show promise as 
components of vehicles for emerging nanomedicines. In contrast to other materials 
explored for drug encapsulation and delivery, proteins show enormous functional 
flexibility that can be pre-designed, engineered, combined and adapted to specific 
situations. Functions such as cell surface receptor binding, nucleic acid condensation, 
membrane crossing and nuclear delivery have been identified in natural peptides or 
protein domains, and can be incorporated to fully de novo designed constructs in an 
attempt to mimic viral infectious activities. However, protein self-assembling has been 
largely reluctant to engineering. Therefore, natural constructs, initially viruses and VLPs 
and lately BMCs, have been adapted to deliver nucleic acids, therapeutic proteins and 
chemicals (Table 3). So far, the extent of manipulation of these natural nanocages is 
limited and restricted by the architectonic constraints imposed by fine protein-protein 
contacts derived from long-term evolution. The recent emerging of bioinspired, protein-
based constructs with regulatable self-organizing properties, namely multifunctional 
modular proteins and IBs, opens a door for a more versatile, functional and 
architectonic control of drug vehicles (Table 3). Since the protein sequence and 
functions, including those governing self-assembling, can be easily manipulated by 
conventional genetic engineering, the progressive comprehension of the mechanics of 
protein-protein contacts and supramolecular organization in recombinant nanocages 
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and the development of architectonic tags should permit the so far neglected de novo 
design and biofabrication of bioinspired, fully biocompatible, multifunctional constructs, 
with utility in nanomedicines and personalized medicine for the targeted delivery of 
chemicals, therapeutic proteins and innovative drugs. 
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Figure legends:  
 
Figure 1. Hierarchical assembly of natural, non-viral protein nano-cages. A) 
Schematic model showing the hierarchical assembly of a typical bacterial 
microcompartment. Facets of these icosahedral nano-cagesBMCs are usually made of 
one type of protein (in green) that self-assembles to render hexamers. The shape of 
such hexamers is tailored for further side-by-side assembly into a flat molecular layer. 
On the other hand, vertices are formed by pentamers resulting of the self-assembly of 
a different protein (in blue). BMC sizes can range from 20-25 nm for the encapsulin 
shell to 100–150 nm for carboxysomes. B) Eukaryotic vaults (a hollow, barrel-like 
structure) are formed by the assembly of two identical cup-like halves joined at their 
open ends (right figure). Each half vault is in turn composed of a single eight-petaled, 
flower-like structure, which is folded into a “cup-shaped” half vault. Each petal is 
composed of six copies of the MVP protein (left figure). Adapted from Kedersha et al. 
(1991), The Journal of Cell Biology, Volume 112 (2): 225 -235. 
 
 
Figure 2. Intracellular protein delivery mediated by bacterial IBs. IBs formed by a 
variant of the green fluorescent protein (GFP) crossing cytosolic (red) and nuclear 
(blue) membranes of cultured HeLa cells, observed in a 3D confocal reconstruction. 
IBs purified from produced bacteria as described (Rodriguez-Carmona, Cano-Garrido, 
Seras-Franzoso, Villaverde, & Garcia-Fruitos, 2010) were suspended in cell culture 
media and exposed to HeLa cells for several hours. Precise methodological details can 
be found elsewhere (Vazquez et al., 2012). The image is taken from reference 
(Villaverde et al., 2012).  
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